Analisis Karakteristik Klinis dan Efektifitas Terapi Antiplatelet pada Pasien Stroke berulang di Rumah Sakit X

Rahmawati Raising; Oktaviarika Dewi Hermawatiningsih

doi:10.30591/pjif.v14i2.8723

Analisis Karakteristik Klinis dan Efektifitas Terapi Antiplatelet pada Pasien Stroke berulang di Rumah Sakit X

Rahmawati Raising, Oktaviarika Dewi Hermawatiningsih

Abstract

Recurrent ischemic stroke poses a significant challenge in clinical practice due to its association with high rates of disability and mortality. Antiplatelet therapy serves as the cornerstone of secondary stroke prevention, yet its effectiveness is influenced by patients' clinical characteristics. This study aimed to analyze the relationship between clinical characteristics and the effectiveness of antiplatelet therapy in recurrent stroke patients at Hospital X. Methode A retrospective observational study with a case-control design was conducted. Data were collected from medical records of patients meeting inclusion criteria and analyzed descriptively and inferentially using the Kolmogorov-Smirnov normality test and Chi-Square test. Results showed that the majority of recurrent stroke patients were female (64%), with the dominant age group being 46–65 years (63%), and 66% had a history of non-hemorrhagic stroke. The longest mean time to recurrent stroke was observed in patients receiving a combination of aspirin and clopidogrel (410.54 days), followed by aspirin monotherapy (359.95 days) and clopidogrel monotherapy (330.82 days). However, these differences were not statistically significant (p = 1.000). Conclusion, recurrent stroke patients exhibited high-risk profiles characterized by female predominance, middle-aged to elderly demographics, and a high prevalence of ischemic stroke and hypertension history. While combination antiplatelet therapy (aspirin-clopidogrel) showed numerically longer recurrence-free intervals compared to monotherapies, no statistically significant difference was found among the three treatment groups.

Keywords

Recurrent stroke, antiplatelet, aspirin, clopidogrel, clinical characteristics

Full Text:

References

C. O. Johnson et al., “Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016,” Lancet Neurol., vol. 18, no. 5, hal. 439–458, 2019, doi: 10.1016/S1474-4422(19)30034-1.

Riskesdas, “Hasil Riset Kesehatan Dasar Tahun 2018,” Kementrian Kesehat. RI, vol. 53, no. 9, hal. 1689–1699, 2018.

M. Kolmos, L. Christoffersen, dan C. Kruuse, “Recurrent Ischemic Stroke – A Systematic Review and Meta-Analysis,” J. Stroke Cerebrovasc. Dis., vol. 30, no. 8, 2021, doi: 10.1016/j.jstrokecerebrovasdis.2021.105935.

J. J. McNeil et al., “Effect of Aspirin on All-Cause Mortality in the Healthy Elderly,” N. Engl. J. Med., vol. 379, no. 16, hal. 1519–1528, 2018, doi: 10.1056/nejmoa1803955.

T. D. Jeong et al., “CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel,” J. Stroke Cerebrovasc. Dis., vol. 24, no. 2, hal. 440–446, 2015, doi: 10.1016/j.jstrokecerebrovasdis.2014.09.014.

N. Rakhmawati, Paryono, dan I. Setyaningsih, “Resistensi Antiplatelet pada Stroke Iskemik,” Berk. Neurosains, vol. 18, no. 1, hal. 1–7, 2019.

S. Wisastry, I. Alifiar, dan C. D. Salasanti, “Analisis Kejadian Stroke Berulang Pada Pasien Yang Menggunakan Antiplatelet Di Rumah Sakit X Ciamis,” J. Farm. Lampung, vol. 6, no. 2, hal. 46–55, 2022.

E. Rosanti, I. Alifiar, dan C. D. Salasanti, “Analisis Kejadian Stroke Berulang pada Pasien yang Menggunakan Antiplatelet di RS X Kota Tasikmalaya,” vol. 15, no. 2, hal. 129–135, 2024.

R. A. A. Putri et al., “Penggunaan Dapt (Dual Antiplatelet) Pada Cva (Cerebrovascular Accident) Trombosis Atau Stroke Iskemik Dengan Riwayat Pjk (Penyakit Jantung Koroner),” vol. 4, hal. 1–23, 2016.

K. Idacahyati dan I. Alifiar, “Cost Minimize Analysis Penggunaan Antiplatelet Pada Pasien Stroke,” J. Ilm. Farm. Farmasyifa, vol. 3, no. 2, hal. 113–120, 2020.

L. A. Fauzi, W. Kushartanti, dan N. I. Arovah, “Gambaran Terapi dan Kepatuhan Obat Pasien Pasca Stroke Rawat Jalan Di RSUD Taman Husada Bontang Overview of Therapy and Medication Adherence in Outpatient Post-Stroke Patients at RSUD Taman Husada Bontang,” J. Farm., vol. 7, no. 2, hal. 239–247, 2025.

R. Raising, O. D. Hermawatiningsih, dan D. M. Qibtiah, “A comparison study between single aspirin antiplatelet and single clopidogrel antiplatelet on average period of recurrent stroke dr. Sayidiman Magetan,” Media Farm. J. Ilmu Farm., vol. 19, no. 1, hal. 49, 2022, doi: 10.12928/mf.v19i1.20639.

S. S. Martin et al., 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data from the American Heart Association, vol. 149, no. 8. 2024.

J. Y. Chung, B. N. Lee, Y. S. Kim, B. S. Shin, dan H. G. Kang, “Sex differences and risk factors in recurrent ischemic stroke,” Front. Neurol., vol. 14, no. 2, 2023, doi: 10.3389/fneur.2023.1028431.

X. Guo et al., “Sex based differences in long- term out comes after stroke: A meta-analysis,” Plus One, 2023.

K. A. Friede et al., “Influence of sex on platelet reactivity in response to aspirin,” J. Am. Heart Assoc., vol. 9, no. 14, 2020, doi: 10.1161/JAHA.119.014726.

T. G. Rahayu, “Analisis Faktor Risiko Terjadinya Stroke Serta Tipe Stroke,” Faletehan Heal. J., vol. 10, no. 01, hal. 48–53, 2023, doi: 10.33746/fhj.v10i01.410.

B. Tamam, “Faktor Risiko Terhadap Kejadian Stroke Di Rsud Dr. Koesnadi Bondowoso Diajukan,” Fakt. Risiko Terhadap Kejadian Stroke Di Rsud Dr. Koesnadi Bond., hal. 12–26, 2020.

R. Oza, K. Rundell, dan M. Garcellano, “Recurrent Ischemic Stroke: Strategies for Prevention,” Am. Fam. Physician, vol. 96, no. 7, hal. 436–440, 2017.

G. Mancia et al., “2018 ESC/ESHGuidelines for themanagement ofarterial hypertension,” Eur. Heart J., vol. 39, no. 6, hal. 1105–1187, 2018, doi: 10.1097/HJH.0b013e3281fc975a.

Y. Xia, H. Liu, dan R. Zhu, “Risk factors for stroke recurrence in young patients with first-ever ischemic stroke: A meta-analysis,” World J. Clin. Cases, vol. 11, no. 26, hal. 6122–6131, 2023, doi: 10.12998/wjcc.v11.i26.6122.

K. S. Hong, “Blood pressure management for stroke prevention and in acute stroke,” J. Stroke, vol. 19, no. 2, hal. 152–165, 2017, doi: 10.5853/jos.2017.00164.

Y. Wang et al., “Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial one-year outcomes,” Circulation, vol. 132, no. 1, hal. 40–46, 2015, doi: 10.1161/CIRCULATIONAHA.114.014791.

N. F. Chi et al., “Comparison between aspirin and clopidogrel in secondary stroke prevention based on real-world data,” J. Am. Heart Assoc., vol. 7, no. 19, 2018, doi: 10.1161/JAHA.118.009856.

S. Octariani, D. Mayasari, dan Adam M. Ramadhan, “Kajian Literatur: Perbandingan Efektivitas Antiplatelet Kombinasi Aspirin_Clopidogrel dan Aspirin pada Stroke Iskemik,” Proceeding Mulawarman Pharm. Conf., no. April 2021, hal. 135–138, 2019, [Daring]. Tersedia pada: http://prosiding.farmasi.unmul.ac.id/index.php/mpc/article/view/416/399.

I. D. G. R. C. Putra, E. A. Pramudita, R. T. Pinzon, dan K. Widyo, “The correlation between compliance medication Of antiplatelet drugs aspirin with recurrent ischemic stroke at Bethesda Hospital in Yogyakarta (SKripsi),” Universitas Kristen Duta Wacana Yogyakarta, 2016.

S. Lukas dan A. Pravita, “Comparison of the Effectiveness of Using Clopidogrel Antiplatelet Drug and Clopidogrel Combination With Aspilet in Iskemic Stroke Patients in Rsud Kab. Bekasi,” Soc. Clin. Pharm. Indones. J., vol. 5, no. 1, hal. 1–8, 2020.

DOI: https://doi.org/10.30591/pjif.v14i2.8723